RespireRx Pharmaceuticals Inc (RSPI)

[Market_Fest4]

I agree with Al David, the Greatful Dead hippy himself. COR should be focused on Ampakines, period. The idea that they are considering diversifying away from ampakines is disturbing either because: a) they have no confidence going forward in Ampas, or b) they have a poor grasp on reality. Neither one of these options give me much faith in Stoll and his ilk. But, it this price, why sell after 12 years?

The reality is COR is a one-trick pony and that trick is Ampas. We, the holders, are "all-in". If we manage, despite all of the obstacles faced, to suceed and Ampas survive and thrive, then management has my blessing to diversify with in-licensing on their way to becoming the next Amgen. But, today's reality is we live and die with Ampas. Any management that doesn't get that is incompetent!

MF4